title: Efficacy of low-dose celecoxib in patients with acute pain.
abstract: The sore throat pain model was used to evaluate single-dose effects of celecoxib 50 and 100 mg over 6 hours in the treatment of acute pharyngeal pain. Multiple-dose effects of 50-mg bid and 100 mg followed by 50 mg over 6 to 24 hours were also evaluated. Under double-blind, randomized, placebo-controlled conditions, 269 adults with confirmed acute pharyngitis rated throat pain intensity, throat soreness, difficulty swallowing, and sore throat pain relief over 24 hours. For the primary efficacy analysis (SPID2), patients receiving celecoxib 100 mg during the first 2 hours after the first dose had significantly higher mean scores than patients in the placebo group (P < .0003). Efficacy was also demonstrated for celecoxib 50 and 100 mg compared with placebo for all end points (including total pain relief, summed pain intensity differences, total reduction of throat soreness, and difficulty swallowing) at all time points after the first dose and after the second 50-mg dose (P < .01). There were no differences between the dosage regimens, although a supplementary 50-mg dose of celecoxib 6 to 12 hours after the first dose appeared to provide additional efficacy over 24 hours. No serious adverse events (AEs) or discontinuations due to an AE were reported. The results of this study demonstrate that in this pain model, celecoxib is a well tolerated and efficacious analgesic in 50- and 100-mg doses.
  
  
  CONCLUSIONS
  In a double-blind, randomized, placebo-controlled trial utilizing the sore throat pain model, low-dose celecoxib (50- and 100-mg doses) was well tolerated and provided effective analgesia in patients with acute pain.
authors: Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, USA. bschachtel@SRCresearch.net
authors: Bernard P
authors: BP
authors: Schachtel
authors: Dorothy
authors: D
authors: McCabe
authors: Manuela
authors: M
authors: Berger
authors: Richard
authors: R
authors: Zhang
authors: Kathleen M
authors: KM
authors: Sanner
authors: Laurie
authors: L
authors: Savino
authors: Jeanne
authors: J
authors: Rizouk
authors: Emily P
authors: EP
authors: Schachtel
mesh_terms: D000293:Adolescent; D000328:Adult; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D010612:Pharyngitis / Q000150:complications / Q000188:drug therapy; D011720:Pyrazoles / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D055815:Young Adult
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib